Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Third dose of messenger RNA vaccines found to increase serological immunity in hematological malignancy patients

In a new study, researchers quantified the serological responses following the third dose of mRNA-based COVID-19 vaccines in patients with hematological malignancies.

12 Apr 2022

Early COVID-19 reinfections possible within 60 days of initial infection

Researchers reported that COVID-19 reinfections could occur within 60 days of the initial infection.

12 Apr 2022

Unique heightened aggregation of SARS-CoV-2 Delta variant spike pseudotyped particles

A recent study illustrated the enhanced distinct clustering of pseudotyped particles (PPs) expressing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant.

12 Apr 2022

NVX-CoV2373 vaccine found to induce functional SARS-CoV-2-specific T cell responses

In a recent study researchers evaluated the T cell responses elicited by full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein vaccine NVX-CoV2373.

12 Apr 2022

Alternative anti-HIV strategy generates promising results in a phase I clinical trial

vaccines against the virus, but unfortunately, HIV has numerous defense mechanisms that prevent a person's immune system from mounting an effective response following HIV vaccination.

11 Apr 2022

Nanocell COVID-19 vaccine elicits potent neutralizing response

A new study describes the high level of neutralizing antibodies elicited by a nanocell vaccine against SARS-CoV-2 in vitro, in vivo, and human studies.

11 Apr 2022

Chromatin accessibility as an early marker of severe COVID-19

A new study explores the possible use of chromatin remodeling in predicting a severe clinical trajectory for COVID-19.

11 Apr 2022

NK cells combined with bispecific antibody achieve effective responses in patients with lymphoma

Researchers from The University of Texas MD Anderson Cancer Center showed that natural killer (NK) cells derived from donated umbilical cord blood, combined with a novel bispecific antibody known as AFM13 that targets CD16A and CD30, achieved effective responses in patients with pretreated and refractory CD30+ lymphoma.

11 Apr 2022

Vaccines safely protect IBD patients from COVID-19

COVID-19 vaccines taken by people with inflammatory bowel disease (IBD), which affects millions worldwide, safely and effectively protects them from the SARS-Cov-2 virus, a Rutgers study finds.

11 Apr 2022

SARS-CoV-2 Omicron BA.2 sublineage outbreak aggravated by low population immunity in Hong Kong

A new study illustrated that inadequate population immunity exacerbated the SARS-CoV-2 Omicron BA.2 sublineage outbreak in Hong Kong.

11 Apr 2022

The human antibody response to the SARS-CoV-2 spike protein N-terminal domain in a group of previously infected individuals

Researchers evaluated the human antibody response to the NTD of the S protein by investigating a group of individuals who had previously been infected with SARS-CoV-2 or who had received an mRNA vaccine.

11 Apr 2022

Ultralong bovine antibody targets cryptic and conserved epitope on SARS-CoV and SARS-CoV-2

Researchers identified an ultralong bovine antibody that neutralizes SARS-CoV-2 and SARS-CoV.

11 Apr 2022

New research on SARS-CoV-2 Omicron variant mutations and sotrovimab therapy

A recent study posted to the medRxiv* preprint server assessed the impact of sotrovimab treatment on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant-infected immunocompromised (IC) patients.

11 Apr 2022

Vaccine-induced blood clots may be the result of genetics, study finds

The rare blood clot side-effect associated with some COVID-19 vaccines could be the result of genetics, new research has found, paving the way for a potential genetic screening test.

11 Apr 2022

S-Nitrosylation of ACE2 inhibits binding of SARS-CoV-2 spike protein

In a recent study posted to the bioRxiv* preprint server, researchers developed aminoadamantane nitrates compounds that inhibit the ion channels formed by the envelope (E) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and enable targeted drug delivery of nitric oxide (NO)-related group for S-nitrosylation of host angiotensin-converting enzyme 2 (ACE2), which would inhibit ACE2 binding with the viral spike (S) protein and thereby inhibit viral replication in the host.

11 Apr 2022

Immunocompromised hosts with Delta/Omicron co-infections

A recent study posted to the medRxiv* preprint server examined clinical cases of co-infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta/Omicron variants and Omicron BA.1/ BA.2 sublineages in immunocompromised (IC) patients.

10 Apr 2022

Challenges, unmet needs and future opportunities in COVID-19 therapeutics

In a recent article published in the journal Proceedings of the National Academy of Sciences (PNAS), researchers reviewed the present-day therapeutic landscape of coronavirus disease 2019 (COVID-19) and addressed future opportunities to overcome challenges that hinder drug development and improve the global preparedness for future pandemics.

10 Apr 2022

A novel PLpro inhibitor as a broad-spectrum anti-coronavirus agent

Researchers identify a potentially effective compound against COVID-19 against the SARS-CoV-2 PLpro.

10 Apr 2022

NK cells complexed with bispecific antibody elicit high response rate in patients with resistant lymphomas

Natural killer (NK) cells derived from cord blood that were activated and complexed with a CD30/CD16A bispecific antibody elicited an 89 percent overall response rate in patients with relapsed or refractory CD30+ lymphoma, according to results from a phase I/II clinical trial presented at the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

NSCLC patients treated with KRAS G12C inhibitor sotorasib may receive long-term clinical benefit

Patients with non-small cell lung cancer (NSCLC) treated with the KRAS G12C inhibitor sotorasib (Lumakras) had a two-year overall survival rate of 32.5 percent, according to data from the CodeBreaK 100 clinical trial presented during the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

Antibody News and Research

Further Reading

Third dose of messenger RNA vaccines found to increase serological immunity in hematological malignancy patients

Early COVID-19 reinfections possible within 60 days of initial infection

Unique heightened aggregation of SARS-CoV-2 Delta variant spike pseudotyped particles

NVX-CoV2373 vaccine found to induce functional SARS-CoV-2-specific T cell responses

Alternative anti-HIV strategy generates promising results in a phase I clinical trial

Nanocell COVID-19 vaccine elicits potent neutralizing response

Chromatin accessibility as an early marker of severe COVID-19

NK cells combined with bispecific antibody achieve effective responses in patients with lymphoma

Vaccines safely protect IBD patients from COVID-19

SARS-CoV-2 Omicron BA.2 sublineage outbreak aggravated by low population immunity in Hong Kong

The human antibody response to the SARS-CoV-2 spike protein N-terminal domain in a group of previously infected individuals

Ultralong bovine antibody targets cryptic and conserved epitope on SARS-CoV and SARS-CoV-2

New research on SARS-CoV-2 Omicron variant mutations and sotrovimab therapy

Vaccine-induced blood clots may be the result of genetics, study finds

S-Nitrosylation of ACE2 inhibits binding of SARS-CoV-2 spike protein

Immunocompromised hosts with Delta/Omicron co-infections

Challenges, unmet needs and future opportunities in COVID-19 therapeutics

A novel PLpro inhibitor as a broad-spectrum anti-coronavirus agent

NK cells complexed with bispecific antibody elicit high response rate in patients with resistant lymphomas

NSCLC patients treated with KRAS G12C inhibitor sotorasib may receive long-term clinical benefit

Industry Focus eBook - Cell biology (5th edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo